Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery
Small · 2024
DOI: 10.1002/smll.202400815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Yulia Eygeris und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR, 97201, USA. Hauptthemen laut MEDLINE: RNA, Messenger, Retina, Nanoparticles, Gene Editing. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NEI NIH HHS, ODCDC CDC HHS.
Abstract (Originalsprache)
Complete encapsulation of nucleic acids by lipid‐based nanoparticles (LNPs) is often thought to be one of the main prerequisites for successful nucleic acid delivery, as the lipid environment protects mRNA from degradation by external nucleases and assists in initiating delivery processes. However, delivery of mRNA via a preformed vesicle approach (PFV‐LNPs) defies this precondition. Unlike traditional LNPs, PFV‐LNPs are formed via a solvent‐free mixing process, leading to a superficial mRNA localization. While demonstrating low encapsulation efficiency in the RiboGreen assay, PFV‐LNPs improved delivery of mRNA to the retina by up to 50% compared to the LNP analogs across several benchmark formulations, suggesting the utility of this approach regardless of the lipid composition. Successful mRNA and gene editors’ delivery is observed in the retinal pigment epithelium and photoreceptors and validated in mice, non‐human primates, and human retinal organoids. Deploying PFV‐LNPs in gene editing experiments result in a similar extent of gene editing compared to analogous LNP (up to 3% on genomic level) in the Ai9 reporter mouse model; but, remarkably, retinal tolerability is significantly improved for PFV‐LNP treatment. The study findings indicate that the LNP formulation process can greatly influence mRNA transfection and gene editing outcomes, improving LNP treatment safety without sacrificing efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR, 97201, USA.
- Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, OR, 97201, USA.
- Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, 97006, USA.
- Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, 97201, USA.
ORCID-Profile: Yulia Eygeris, Michael I Henderson, Antony Jozić, Rene Reynaga, Kathleen R Chirco, Renee C Ryals, Gaurav Sahay
Förderung
- NIH HHS
- NEI NIH HHS
- ODCDC CDC HHS
- NIGMS NIH HHS
- NCRR NIH HHS
- Oregon National Primate Research Center
- Research to Prevent Blindness
- National Eye Institute
Zitieren
APA
Eygeris, Y., Henderson, M. I., Curtis, A. G., Jozić, A., Stoddard, J., Reynaga, R., Chirco, K. R., Su, G. L., Neuringer, M., Lauer, A. K., Ryals, R. C., & Sahay, G. (2024). Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery. Small. https://doi.org/10.1002/smll.202400815
Vancouver
Eygeris Y, Henderson MI, Curtis AG, Jozić A, Stoddard J, Reynaga R, et al. Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery. Small. 2024. doi:10.1002/smll.202400815
BibTeX
@article{Eygeris2024,
author = {Eygeris, Yulia and Henderson, Michael I and Curtis, Allison G and Jozić, Antony and Stoddard, Jonathan and Reynaga, Rene and Chirco, Kathleen R and Su, Grace Li-Na and Neuringer, Martha and Lauer, Andreas K and Ryals, Renee C and Sahay, Gaurav},
title = {Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202400815}
}
EUVIMED